<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE7A3D6-AEA1-4546-A2B4-0FB58F5A37C5"><gtr:id>FAE7A3D6-AEA1-4546-A2B4-0FB58F5A37C5</gtr:id><gtr:name>European Respiratory Society (ERS)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE7A3D6-AEA1-4546-A2B4-0FB58F5A37C5"><gtr:id>FAE7A3D6-AEA1-4546-A2B4-0FB58F5A37C5</gtr:id><gtr:name>European Respiratory Society (ERS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1E62C76E-8080-4806-9F41-5619D3B6E530"><gtr:id>1E62C76E-8080-4806-9F41-5619D3B6E530</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Chalmers</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800428"><gtr:id>E91FE5DE-099B-4247-A877-C1BFD01169A6</gtr:id><gtr:title>An investigation of L-ficolin in adult bronchiectasis:- a potential innovative new therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800428</gtr:grantReference><gtr:abstractText>FIGHTING LUNG INFECTION WITHOUT ANTIBIOTICS
Laennec discovered bronchiectasis in 1819. There are no effective treatments apart from antibiotics for chest infections. With the increasing use of antibiotics there is also increasing antibiotic resistance. This problem has gained widespread media attention, particularly with emerging problems like MRSA, and tackling this is a priority worldwide.
We propose to study an innovative new treatment called L-Ficolin. This is a natural protein made by the liver, which helps to fight bacteria, viruses and fungal infections. Studies in our department have found that 16% of patients with bronchiectasis are deficient in this protein. 
In good health the patient?s own body helps to keep the airways free of infection. Two-thirds of patients with bronchiectasis are permanently infected with bacteria, however, and this leads to daily symptoms of cough, sputum production and chest infections. 
We propose a detailed study of L-Ficolin. In the laboratory we will explore the ability of L-Ficolin to help the body to remove bacteria and we will experiment in the laboratory whether treatment with L-Ficolin can help the body to fight infection. This offers a fresh new therapy for this disabling disease, one that is natural and not an antibiotic.
If proven to be of benefit, L-Ficolin may have a role in treating other lung infections such as pneumonia or tuberculosis, two of the leading causes of death worldwide.</gtr:abstractText><gtr:technicalSummary>INTRODUCTION: Bronchiectasis is a common disabling chronic lung disease characterized by irreversibly damage with dilatation of the bronchi and persistent microbial colonization of the normally sterile lower respiratory tract. Over 2/3 of patients are chronically colonised with bacteria. Bacterial colonisation is known to perpetuate a vicious cycle of airways inflammation and further tissue damage. Bronchiectasis is associated with significant morbidity, mortality and use of healthcare resources for both children and adults, and new treatments to halt disease progression are needed. Increasing anti-microbial resistance is a major problem worldwide. Novel non-antibiotic therapies for lung infection are needed.
L-ficolin is a recently described pattern recognition receptor and has been shown to promote phagocytosis of Gram-negative and Gram-positive bacteria, fungi, viruses, and particulate allergens. 
We found that bronchiectasis was associated with low serum concentrations of L-ficolin (19/118 (16%) compared with 6/170 (3.5%) of controls; P=0.0004). L-ficolin is a recently described soluble protein that is important in the body?s initial (innate) defense against micro-organisms. Naturally occurring polymorphisms in the L-ficolin gene influence both the production and function of the protein. We aim to determine the role of L-ficolin in bronchiectasis.
HYPOTHESES: (1) Deficiency or impaired function of L-ficolin predisposes to microbial colonization of the airways. (2) Deficiency or impaired function of L-ficolin function leads to impaired clearance of apoptotic inflammatory cells and microbial organisms, which results in persistent airways inflammation. 
METHODS: 100 patients will be recruited from a large specialist bronchiectasis clinic (&amp;gt; 300 patients) based at the Royal Infirmary of Edinburgh. Recruitment criteria will include idiopathic/post-infective non-cystic fibrosis bronchiectasis. 50 will be chronically colonised and 50 will be non-colonised. A healy control group (50 patients) will also be recruited. We will determine the association between L-ficolin and susceptibility to bronchiectasis by analysis of serum and sputum levels of L-ficolin and L-ficolin genetic polymorphisms. We will determine the functionality of L-ficolin in patients? sputum by assaying phagocytosis of apoptotic neutrophils by macrophages, microbial adherence to epithelial cells, and microbial phagocytosis and killing. We will explore in vitro how supplementation with L-ficolin can rescue defects seen in these assays.
TRAINING: This project will provide first class training in organizing and running a clinical study, processing sputum and sera, ELISA, cell and bacterial culture, purification of leukocytes from peripheral blood, analysis of apoptosis and phagocytosis, Western blotting, DNA extraction and PCR, and data analysis and presentation.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-02</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>186570</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Respiratory Society (ERS)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EMBARC- The European Bronchiectasis Network</gtr:description><gtr:id>372A3F8F-8BBC-4386-9854-D0D9D2AA9EB8</gtr:id><gtr:impact>Major output is the iABC consortium, a 60m euro IMI grant for the development of inhaled antibiotics for bronchiectasis</gtr:impact><gtr:outcomeId>545538b425bfc2.90174486-1</gtr:outcomeId><gtr:partnerContribution>International collaborative network of researchers for translational and clinical research in bronchiectasis</gtr:partnerContribution><gtr:piContribution>I founded and now chair the European Bronchiectasis Network https:\\www.bronchiectasis.eu</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Bronchiectasis patient support group talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9B08493B-60CE-4306-8EDC-FE69EEF436E6</gtr:id><gtr:impact>50 patients attended a talk about research into respiratory diseases leading to a wide-ranging discussion about the relevance of research to patients. The patient group have now asked for this to become an annual talk to the group updating them on ongoing research.

Recruitment to respiratory studies has increased and the patient group have asked us to give a regular talk to the patient group about ongoing research.</gtr:impact><gtr:outcomeId>osgkkeT5BSL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>126214</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5D242DB6-9FB0-4E67-8FB1-F82472B45106</gtr:id><gtr:outcomeId>58b681c44c3c31.46015974</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chief Scientists Office, Project grant</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>840EB92B-B579-4D5E-8FD7-33D5C74143AA</gtr:id><gtr:outcomeId>CEBu3yy4wB50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>256000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pregnancy zone protein and the lung-investigating gender differences in the lung microbiome</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:fundingRef>CAF/16/09</gtr:fundingRef><gtr:id>A9D950A8-33E9-4C71-8789-626F44A1A9D5</gtr:id><gtr:outcomeId>58b681698d5f35.11191484</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A large clinical database of patients with non-cystic fibrosis bronchiectasis containing detailed clinical, microbiological and radiological data that will be an invaluable resource for future research</gtr:description><gtr:id>57C0DAA6-F9B6-4CD6-8FE9-EB026338F825</gtr:id><gtr:impact>We anticipate this resource will provide a wealth of new information that will enhance our understanding of this disease.</gtr:impact><gtr:outcomeId>ZLc6cHWgqZP</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Clinical bronchiectasis cohort database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Over 500 patients have supplied DNA and blood samples to a biobank linked to our clinical bronchiectasis database. This resource will facilitate a number of studies into disease associations and disease modifiers in non-cystic fibrosis bronchiectasis.</gtr:description><gtr:id>E9AC0320-CDA2-4F79-B9C4-4855A5A595F2</gtr:id><gtr:impact>We have already obtained further funding to study single nucleotide polymorphisms associated with bronchiectasis in this cohort and will be able to pursue further studies as a result of the development of this clinical resource.</gtr:impact><gtr:outcomeId>sYafnGocmTP</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biobank of bronchiectasis DNA and blood samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FFEA0586-FA3C-4EDD-81EF-E51395E72A33</gtr:id><gtr:title>Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>bbHeNad3zWU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6606C2B-8FB7-4E13-A173-9AE5B982D16C</gtr:id><gtr:title>Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_14178_28_23076388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B537928-CC09-4C4B-9B31-D58EA104DF59</gtr:id><gtr:title>Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>pm_55f94509450f49b90</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40016F70-B751-4D9D-913B-C5565A7C852D</gtr:id><gtr:title>Human L-ficolin (ficolin-2) and its clinical significance.</gtr:title><gtr:parentPublicationTitle>Journal of biomedicine &amp; biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40b4645bd44e7554107ddec721ec54f0"><gtr:id>40b4645bd44e7554107ddec721ec54f0</gtr:id><gtr:otherNames>Kilpatrick DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1110-7243</gtr:issn><gtr:outcomeId>pm_14178_28_22500076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C641F0DB-AAC8-4BAE-A99D-40BF9013CCD6</gtr:id><gtr:title>Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>pm_14178_28_23088941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F591832C-3B38-4C6A-9E4C-717F7765878B</gtr:id><gtr:title>Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1838bc97f7415dab93171128fab5c33c"><gtr:id>1838bc97f7415dab93171128fab5c33c</gtr:id><gtr:otherNames>Mandal P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_14178_28_23019590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1045825-78A9-4A03-AD01-2AF8BBFFA2BD</gtr:id><gtr:title>The bronchiectasis severity index. An international derivation and validation study.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5455379fdcd152.76165625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>356C6C77-284C-470B-B970-AC4D897A2EE0</gtr:id><gtr:title>Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f64f39cc55653d211eaffe32e196558a"><gtr:id>f64f39cc55653d211eaffe32e196558a</gtr:id><gtr:otherNames>McDonnell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a31e19e36fd30.26021341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>141EA53C-50D6-45A6-82F2-9FCB78817025</gtr:id><gtr:title>Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43026993ef7e0ba7f12c8f85310b465a"><gtr:id>43026993ef7e0ba7f12c8f85310b465a</gtr:id><gtr:otherNames>Chalmers JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_14178_28_22744718</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800428</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>